This collectively suggests that reactivation of AKT signalling is critical for these tumour cells, indeed treatment with the allosteric AKTi miransertib (ARQ092) and the ATP-competitive AKTi ipatasertib re-sensitised tumour cells expressing these double mutants39. The gene discussed is AKT1; the disease is neoplasm.